By

Ivonne
February 27, 2024ByIn

Recommendations for the draft EU Parliament’s ENVI Committee reports for the pharma package 

2024-02-27_ECL_EFPN_Recommendations-for-the-draft-ENVI-Committee-reports-for-the-pharma-package
Continue Reading
February 19, 2024ByIn

Stakeholders call for the protection of the hospital exemption 

2024-02-19_Joint-Statement-Hospital-Exemption
Continue Reading
September 23, 2023ByIn

Recommendations for a new Directive on medicinal products for human use  

2023-09-14-ECL-position-on-the-proposal-for-EU-Pharma-Directive
Continue Reading
September 14, 2023ByIn

Recommendations for the EU procedures for the authorisation and supervision of medicinal products for human use

2023-09-14-ECL-position-on-the-proposal-for-EU-Pharma-Regulation
Continue Reading
May 25, 2023ByIn

Factsheet: Let’s talk about weight and cancer

Continue Reading
March 29, 2023ByIn

Letter to President von der Leyen: Delayed publication of the EU pharmaceutical legislation revision

2023-03-29_Letter-to-President-von-der-Leyen_EU-pharmaceutical-legislation-revision
Continue Reading
March 16, 2023ByIn

Letter: Cancer patients need a patient-centred and fit for purpose pharmaceutical system

2023-03-16_ECL-Anticancer-Fund-EFPN-letter-to-the-European-Commission_Revision-of-the-EU-pharmaceuticals-legislation-1
Continue Reading
March 15, 2023ByIn

ECL and EFPN recommendations for the revision of the EU legislation of medicines for rare diseases  

2023-0316_ECL-and-EFPN-Recommendations_Revision-of-the-EU-legislation-on-medicines-for-rare-diseases
Continue Reading
March 15, 2023ByIn

Infographic: Access to medicines for all patients with rare diseases  

2023-03-16-ECL-EFPN-infographic_revision-EU-legislation-on-medicines-for-rare-diseases
Continue Reading
March 15, 2023ByIn

ECL and Anticancer Fund recommendations for the revision of the EU general pharmaceutical legislation 

2023-03-16_ECL-and-Anticancer-Fund-recommendations_Revision-of-the-EU-general-pharmaceutical-legislation
Continue Reading
1 2 3 4 5 … 11